1. Targeted and efficient DC1s-CTL in vitro treatment kit
DC1s-CTL in vitro treatment kit mainly consists of DC1s-CTL kit and CTL-TP kit
【expected usage】
The DC1s-CTL in vitro processing kit is used for the activation of mononuclear cells isolated from human peripheral blood to obtain a large number of type 1 polarized dendritic cells. Combined with the CTL-TP test kit, a targeted DC vaccine was obtained, and a large number of antigen-specific CTL cells were induced and expanded in vitro.
【Storage conditions and validity period】
When the temperature is 2~8℃, the validity period is 3 months; when the temperature is 20℃, the validity period is 1 year.
【Operation method】
Follow the SOP documents provided by the company in detail.
【Sample requirements】
For the collection of peripheral blood, sodium heparin is preferred as an anticoagulant.
Blood should not exceed 12 hours from collection to operation.
2. Instructions for multiple activation of CIK in vitro treatment kit
【product name】
Generic Name: Multiple Activation CIK In Vitro Processing Kit
Product name: none
English name: Mact-CIK
【Product composition and description】
The Mact-CIK in vitro treatment kit is composed of a complete set of components, such as factors and medium required to obtain multiple activated CIK cells. Its main components are as follows
【expected usage】
Multiple Activated CIK In Vitro Treatment Kit The in vitro treatment kit is mainly used for in vitro treatment of lymphocytes in bone marrow, peripheral blood and umbilical cord blood, and a large number of CIK cells can be obtained by separation and activation.
【Principle of action】
Lymphocytes isolated from bone marrow, umbilical cord blood or peripheral blood are stimulated by specific cytokines and glycolipid molecules, thereby causing a cascade reaction of kinase activation, and finally turning lymphocytes from a quiescent state to a proliferating and activated state. , resulting in a large number of CIK cells.
【Storage conditions and validity period】
When the temperature is 2~8℃, the validity period is 3 months; when the temperature is -20℃, the validity period is 1 year.
【Operation method】
Follow the SOP documents provided by the company in detail.
【Sample requirements】
1. Heparin anticoagulation is preferred for the collection of bone marrow, umbilical cord blood or peripheral blood.
2. The blood should not exceed 24 hours from collection to operation.
【Product performance index】
After induction treatment by the kit, the obtained CIK cells are 30-50% pure, and the cell viability is ≥99%.
3. Instructions for multiple activated DC/CIK in vitro treatment kit
【product name】
Generic Name: Multiple Activated DC/CIK In Vitro Treatment Kit
Product name: none
English name: Mact-DC/CIK
【Product composition and description】
The Mact-DC/CIK in vitro treatment kit is composed of a complete set of components such as factors and culture medium required to obtain multiple activated DC/CIK cells. Its main components are as follows:
【expected usage】
Multiple Activation Mact-DC/CIK In Vitro Treatment Kit The in vitro treatment kit is mainly used for in vitro treatment of lymphocytes in bone marrow, peripheral blood and umbilical cord blood, and separate and activate a large number of DC and CIK cells.
【Principle of action】
Lymphocytes isolated from bone marrow, umbilical cord blood or peripheral blood are induced to obtain mature DC cells through factor induction, and stimulated by specific cytokines and glycolipid molecules to obtain a large number of CIK cells. Then, through the related stimulation of DC cells and CIK cells, a large number of effector cells of DC/CIK to kill the tumor are obtained.
【Storage conditions and validity period】
When the temperature is 2~8℃, the validity period is 3 months, and when the temperature is -20℃, the validity period is 1 year.
【Operation method】
Follow the SOP documents provided by the company in detail.
【Sample requirements】
1. Heparin anticoagulation is preferred for the collection of bone marrow, umbilical cord blood or peripheral blood.
2. The blood should not exceed 24 hours from collection to operation.
【Product performance index】
After induction treatment by the kit, the obtained CIK cells have a purity of 30-50% and a cell viability of ≥99%.
4. High-purity NK in vitro treatment kit
High-purity NK in vitro treatment kit instructions
【product name】
Generic name: Commodity of high-purity NK in vitro treatment kit
name: none
English name: H-NK
【Product composition and description】
The H-NK in vitro treatment kit consists of a complete set of components such as the factor medium required for culturing high-purity NK cells. Its main components are as follows:
【Adaptation symptoms】
1. Except for individual treatment of recurrent tumors in children, the age of the patients is more than 16 years old;
2. Identify patients with malignant tumors, especially tumors with high antigen expression;
3. Patients after tumor surgery;
4. Cancer patients who cannot undergo surgery, radiotherapy or chemotherapy;
5. Cancer patients who have failed radiotherapy and chemotherapy;
6. Comprehensive treatment of tumor patients after radiotherapy and chemotherapy;
7. Leukemia patients after bone marrow transplantation or after chemotherapy remission;
8. Some patients are temporarily unsuitable for surgery, interventional or other treatments.
【expected usage】
This kit is mainly used for the in vitro treatment of mononuclear cells in bone marrow, peripheral blood and umbilical cord blood, and isolation and activation to obtain a large number of high-purity natural killer cells.
【Principle of action】
This product co-cultures mononuclear cells isolated from bone marrow, peripheral blood and umbilical cord blood with cell treatment solution and feeder cells in vitro. Through stimulation of cytokines and feeder cells, the isolated and activated mononuclear cells become natural killers with killing function. cell.
【Storage conditions and validity period】
Storage temperature ≤-20. C, valid for one year.
【Operation method】
Follow the SOP documents provided by the company in detail.
【Sample requirements】
1. For the collection of bone marrow, umbilical cord blood or peripheral blood, heparin uranium is preferred as an anticoagulant.
2. The time from blood collection to operation should not exceed 12 hours.
【Product performance index】
After induction treatment by the kit, the obtained natural killer cell viability is ≥95%, and the cell surface marker CD3-CD56+70%-99%.